Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products
B Kelley, P De Moor, K Douglas, T Renshaw… - Current Opinion in …, 2022 - Elsevier
Highlights•Multiple companies are authorized to treat COVID-19 patients with monoclonal
antibodies (mAbs).•They were discovered, developed, manufactured, tested, and approved …
antibodies (mAbs).•They were discovered, developed, manufactured, tested, and approved …
COVID-19 prophylaxis in immunosuppressed patients: Beyond vaccination
I Gentile, N Schiano Moriello - PLoS Medicine, 2022 - journals.plos.org
COVID-19 prophylaxis in immunosuppressed patients: Beyond vaccination | PLOS Medicine
Skip to main content Advertisement PLOS Medicine Browse Current Issue Journal Archive …
Skip to main content Advertisement PLOS Medicine Browse Current Issue Journal Archive …
Characterization of early-onset severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients who received tixagevimab-cilgavimab …
Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus
disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical …
disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical …
Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti‐spike neutralizing IgG to SARS‐CoV‐2 variants, but preserved antigen …
B Beaton, SC Sasson, K Rankin… - American Journal of …, 2023 - Wiley Online Library
Patients with indolent lymphoma undertaking recurrent or continuous B cell suppression are
at risk of severe COVID‐19. Patients and healthy controls (HC; N= 13) received two doses of …
at risk of severe COVID‐19. Patients and healthy controls (HC; N= 13) received two doses of …
[PDF][PDF] Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models
M Takeshita, H Fukuyama, K Kamada, T Matsumoto… - Iscience, 2022 - cell.com
The use of therapeutic neutralizing antibodies against SARS-CoV-2 infection has been
highly effective. However, there remain few practical antibodies against viruses that are …
highly effective. However, there remain few practical antibodies against viruses that are …
[PDF][PDF] A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques
Background Human monoclonal antibody (mAb) treatments are promising for COVID-19
prevention or therapy. The pre-exposure prophylactic efficacy of neutralizing antibodies that …
prevention or therapy. The pre-exposure prophylactic efficacy of neutralizing antibodies that …
COVID-19 and solid organ transplantation: role of anti-SARS-CoV-2 monoclonal antibodies
A Dhand, RR Razonable - Current Transplantation Reports, 2022 - Springer
Abstract Purpose of Review Solid organ transplant recipients (SOTRs) are ideal candidates
for early treatment or prevention of coronavirus disease 2019 (COVID-19) using anti-SARS …
for early treatment or prevention of coronavirus disease 2019 (COVID-19) using anti-SARS …
Qualification of a Biolayer Interferometry Assay to support AZD7442 resistance monitoring
T Brady, T Zhang, KM Tuffy, N Haskins, Q Du… - Microbiology …, 2022 - Am Soc Microbiol
ABSTRACT AZD7442, a combination of two long-acting monoclonal antibodies
(tixagevimab [AZD8895] and cilgavimab [AZD1061]), has been authorized for the prevention …
(tixagevimab [AZD8895] and cilgavimab [AZD1061]), has been authorized for the prevention …
[PDF][PDF] Characterization of early-onset SARS-CoV-2 infection in immunocompromised patients who received tixagevimab-cilgavimab prophylaxis
Abstract 1 Tixagevimab-cilgavimab is authorized for pre-exposure prophylaxis against
coronavirus 2 disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report …
coronavirus 2 disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report …
Fc-modified SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models
M Takeshita, H Fukuyama, K Kamada, T Matsumoto… - bioRxiv, 2022 - biorxiv.org
The use of therapeutic neutralizing antibodies against SARS-CoV-2 infection has been
highly effective. However, there remain few practical antibodies against viruses that are …
highly effective. However, there remain few practical antibodies against viruses that are …